<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <ArticleTitle>Recent updates on analysis of alteration of Zn level in cancer patients</ArticleTitle>
      <Abstract>Zn micro-nutrient involved in many physiological processes that include enzyme activity, genomic stability, DNA repairing, apoptosis, immunity, neurological function, response to oxidative stress, and cell signaling. The deficiency of trace element Zn may be responsible for the mutation of DNA, tumorigenesis, and carcinoma cell production. The Zn level has been found to decrease in cancer patients as compared to the healthy controls. The various cancer such as breast, ovarion, prostate, lung, Ewing, endometrial, brain and bladder cancer have been co-related with Zinc deficiency. The polymorphism may be corelated with the ZINC deficiency in several cancer patients. The polymorphism has been observed in MT2A, MMP-1, MMP-2, MMP-7, and MMP-13 gene significantly change the Zn levels in the serum of prostate cancer patients. The genotypes GSTM1 and GSTT1 significantly changes the concentration of the Zinc concentration in the lung cancer patients. Polymorphism rs1805502 in the GRIN2B gene in brain significantly low concentration of Zinc in serum. The results of these studies associated with deficiency of zinc in the body may cause DNA damage, mutation in DNA, and tumor growth. This review article provides a detailed description of the deficiency of the Zn element in cancer patients and polymorphisms in genes encoding zinc-dependent proteins associated with different cancer.</Abstract>
      <Keywords>Polymorphism, Cancer, Zinc, DNA, mutation</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14970&amp;title=Recent updates on analysis of alteration of Zn level in cancer patients</Abstract>